Gynecologic Oncology

The official declaration means more funding for research initiatives.

The FDA has accepted a new supplemental biologics license application for pembrolizumab, an anti-PD-1 therapy, as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, who have diseased progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Pregnant women who had cancer previously or currently have cancer were more likely to experience comorbidities and in-hospital complications, depending on cancer type.

The results, according to the study authors, demonstrate that screening the general population for tubal and ovarian cancer each year does not result in a survival benefit.

The American College of Obstetricians and Gynecologists (ACOG) recently published an updated committee opinion regarding morcellation of presumed uterine leiomyoma. Here are the key points.

We hear from Christine Isaacs, MD about the new ASCCP guidelines and what they mean for ob/gyns.

The unmet need for personalized follow-up care due to a wide variety of health burdens after treatment needs to be addressed.

For cervical cancer screening, human papillomavirus (HPV)–based screening modalities detect significantly more abnormal cervical cells than traditional liquid-based cytology (LBC) approaches, according to a study in JAMA Network Open.

Nemvaleukin alfa (Alkermes) was mostly well tolerated and indicated antitumor activity as both monotherapy and in combination with pembrolizumab among patients with advanced solid tumors, according to study results presented at the annual meeting of the American Society of Clinical Oncology (ASCO), held virtually from June 4-8.

“I believe in combinatorial immunotherapeutic regimens in an attempt to increase efficacy and durability of response,” said principal investigator Omid Hamid, MD, director of clinical research and immunotherapy at The Angeles Clinic and Research Institute in Los Angeles, an affiliate of Cedars-Sinai Medical Center.

In honor of International Women’s Day, CURE® compiled some recent news and updates in cancer research that you may have missed.

Researchers from a study published in Cancers discovered a new method of detecting endometrial cancer in women via a simple, non-invasive blood test.

A team of international researchers partnered with the National Cancer Institute and Mayo Clinic to conduct a research opportunity that led to unexpected findings.

On this episode of Pap Talk, Sangini Sheth, MD, MPH discusses the latest research in cervical cancer and HPV.

Total laparoscopic nerve-sparing radical hysterectomy (TL-NSRH) has advantages over open abdominal nerve-sparing radical hysterectomy (OA-NSRH), according to research published in the Journal of Gynecologic Oncology.

This interview features Sangini Sheth, MD, MPH, as she discusses the latest research on HPV and cervical cancer.

Women vaccinated following conization experienced a slightly lower, though not statistically significant, rate of recurrence of high-grade cervical dysplasia, according to a recent study.

In honor of Cervical Cancer Awareness month, Contemporary OB/GYN® will publish weekly slideshows with factual information, statistics, and more.

Since radical hysterectomy does not improve survival, the procedure should be replaced with definitive chemoradiation, according to the ABRAX study published in the European Journal of Cancer.

While no difference was shown in disease-free survival rates between surgical and non-surgical staging methods, laparoscopy benefits patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIB cervical cancer. Surgical staging also has a cancer-specific survival benefit, according to a study published in the International Journal of Gynecological Cancers.

With coronavirus disease 2019 limiting the availability of health resources, research using a comprehensive review and expert opinion has set pandemic treatment protocols for gynecological cancers.

In honor of Cervical Cancer Awareness month, Contemporary OB/GYN® will publish weekly slideshows with factual information, statistics, and more.

“Reaching these women is critical to reduce cervical cancer rates.”

Pembrolizumab plus lenvatinib induced a statistically significant and clinically meaningful improvement in overall survival, progression-free survival, and objective response rate compared with chemotherapy in patients with advanced endometrial cancer after prior systemic therapy in the phase 3 KEYNOTE-775/Study 309 trial.

A new study found that the rate of cancer in adolescents and young adults increased by 29/6% between 1973 and 2015.